vs
ARROWHEAD PHARMACEUTICALS, INC.（ARWR）与Ascendis Pharma A/S（ASND）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是ARROWHEAD PHARMACEUTICALS, INC.的1.0倍（$267.3M vs $264.0M），ARROWHEAD PHARMACEUTICALS, INC.同比增速更快（10461.3% vs 42.3%）
Arrowhead Pharmaceuticals是总部位于美国加利福尼亚州帕萨迪纳的上市生物制药企业，专注于通过RNA干扰（RNAi）作用机制开发创新药物，核心研发管线覆盖乙型肝炎、α-1抗胰蛋白酶缺陷相关肝病及心血管疾病的治疗领域。
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
ARWR vs ASND — 直观对比
营收规模更大
ASND
是对方的1.0倍
$264.0M
营收增速更快
ARWR
高出10419.0%
42.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $264.0M | $267.3M |
| 净利润 | $30.8M | — |
| 毛利率 | — | 90.5% |
| 营业利润率 | 15.5% | — |
| 净利率 | 11.7% | — |
| 营收同比 | 10461.3% | 42.3% |
| 净利润同比 | 117.8% | — |
| 每股收益（稀释后） | $0.22 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARWRASND
| Q4 25 | $264.0M | $267.3M | ||
| Q3 25 | — | $230.7M | ||
| Q2 25 | — | $170.7M | ||
| Q1 25 | — | $109.0M | ||
| Q4 24 | — | $187.8M | ||
| Q3 24 | — | $62.5M | ||
| Q2 24 | — | $38.9M | ||
| Q1 24 | — | $103.6M |
净利润ARWRASND
| Q4 25 | $30.8M | — | ||
| Q3 25 | — | $-65.9M | ||
| Q2 25 | — | $-42.0M | ||
| Q1 25 | — | $-102.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-107.1M | ||
| Q2 24 | — | $-118.1M | ||
| Q1 24 | — | $-141.5M |
毛利率ARWRASND
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 89.5% | ||
| Q2 25 | — | 80.1% | ||
| Q1 25 | — | 82.6% | ||
| Q4 24 | — | 91.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 68.2% | ||
| Q1 24 | — | 92.1% |
营业利润率ARWRASND
| Q4 25 | 15.5% | — | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -33.5% | ||
| Q1 25 | — | -103.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -167.3% | ||
| Q2 24 | — | -370.2% | ||
| Q1 24 | — | -51.2% |
净利率ARWRASND
| Q4 25 | 11.7% | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | — | -24.6% | ||
| Q1 25 | — | -93.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -171.5% | ||
| Q2 24 | — | -303.9% | ||
| Q1 24 | — | -136.6% |
每股收益（稀释后）ARWRASND
| Q4 25 | $0.22 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $715.0M | $665.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $568.4M | $-175.8M |
| 总资产 | $1.6B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARWRASND
| Q4 25 | $715.0M | $665.3M | ||
| Q3 25 | — | $582.2M | ||
| Q2 25 | — | $533.6M | ||
| Q1 25 | — | $559.4M | ||
| Q4 24 | — | $604.3M | ||
| Q3 24 | — | $675.6M | ||
| Q2 24 | — | $279.4M | ||
| Q1 24 | — | $345.9M |
股东权益ARWRASND
| Q4 25 | $568.4M | $-175.8M | ||
| Q3 25 | — | $-188.0M | ||
| Q2 25 | — | $-202.6M | ||
| Q1 25 | — | $-205.0M | ||
| Q4 24 | — | $-114.2M | ||
| Q3 24 | — | $-105.1M | ||
| Q2 24 | — | $-346.8M | ||
| Q1 24 | — | $-257.2M |
总资产ARWRASND
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $819.0M | ||
| Q1 24 | — | $866.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.5M | $58.2M |
| 自由现金流经营现金流 - 资本支出 | $11.3M | — |
| 自由现金流率自由现金流/营收 | 4.3% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.44× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARWRASND
| Q4 25 | $13.5M | $58.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-15.5M | ||
| Q4 24 | — | $-330.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-109.7M |
自由现金流ARWRASND
| Q4 25 | $11.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ARWRASND
| Q4 25 | 4.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ARWRASND
| Q4 25 | 0.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ARWRASND
| Q4 25 | 0.44× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
